Dominion Energy Inc (D)vsGlaxoSmithKline PLC ADR (GSK)
D
Dominion Energy Inc
$66.90
+0.60%
UTILITIES · Cap: $58.46B
GSK
GlaxoSmithKline PLC ADR
$49.72
+1.47%
HEALTHCARE · Cap: $98.26B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 88% more annual revenue ($32.78B vs $17.45B). GSK leads profitability with a 17.8% profit margin vs 16.9%. D appears more attractively valued with a PEG of 2.82. D earns a higher WallStSmart Score of 60/100 (C+).
D
Buy60
out of 100
Grade: C+
GSK
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-33.0%
Fair Value
$48.62
Current Price
$66.90
$18.28 premium
Margin of Safety
-26.6%
Fair Value
$46.22
Current Price
$49.72
$3.50 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 28.7%
Revenue surging 23.1% year-over-year
Strong operational efficiency at 36.3%
Large-cap with strong market position
Every $100 of equity generates 25 in profit
Attractively priced relative to earnings
Areas to Watch
Elevated debt levels
Expensive relative to growth rate
Earnings declined 10.2%
Negative free cash flow — burning cash
1.5% revenue growth
Elevated debt levels
Expensive relative to growth rate
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : D
The strongest argument for D centers on Market Cap, Price/Book, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 28.7%. Revenue growth of 23.1% demonstrates continued momentum.
Bull Case : GSK
The strongest argument for GSK centers on Operating Margin, Market Cap, Return on Equity. Profitability is solid with margins at 17.8% and operating margin at 36.3%.
Bear Case : D
The primary concerns for D are Debt/Equity, PEG Ratio, EPS Growth. Debt-to-equity of 1.78 is elevated, increasing financial risk.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
D profiles as a growth stock while GSK is a value play — different risk/reward profiles.
D carries more volatility with a beta of 0.64 — expect wider price swings.
D is growing revenue faster at 23.1% — sustainability is the question.
GSK generates stronger free cash flow (698M), providing more financial flexibility.
Bottom Line
D scores higher overall (60/100 vs 58/100), backed by strong 16.9% margins and 23.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dominion Energy Inc
UTILITIES · UTILITIES - REGULATED ELECTRIC · USA
Dominion Energy, Inc., commonly referred to as Dominion, is an American power and energy company headquartered in Richmond, Virginia that supplies electricity in parts of Virginia, North Carolina, and South Carolina and supplies natural gas to parts of Utah, West Virginia, Ohio, Pennsylvania, North Carolina, South Carolina, and Georgia. Dominion also has generation facilities in Indiana, Illinois, Connecticut, and Rhode Island.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other UTILITIES - REGULATED ELECTRIC Stocks
Want to dig deeper into these stocks?